MED12 and prostate carcinoma: BRCA2-mutant prostate cancers display genomic instability and a mutational profile more similar to metastatic than localized disease; importantly, BRCA2-mutant prostate cancers show genomic and epigenomic dysregulation of MED12L/MED12 axis, frequently dysregulated in metastatic castration-resistant prostate cancer, and are clearly enriched in BRCA2-mutant prostate cancer harboring IDC [30].